Resveratrol targets in inflammation

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 15, Issue 3, 2015, Pages 186-195

  Inoue, Hiroyasu ^a   Nakata, Rieko ^a  

^a NARA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase; Endothelial nitric oxide synthase; Inflammation; Peroxisome proliferator activated receptor; Resveratrol; SIRT1

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RESVERATROL; SIRTUIN 1; AUTACOID; NONSTEROID ANTIINFLAMMATORY AGENT; STILBENE DERIVATIVE;

ARTICLE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CHEMICAL COMPOSITION; GLYCOLYSIS; HOMEOSTASIS; HUMAN; INFLAMMATION; MACROPHAGE ACTIVATION; NONHUMAN; PENTOSE PHOSPHATE CYCLE; PLANT PRODUCT; PLANT ROOT; STRESS; TRADITIONAL MEDICINE; ULTRAVIOLET RADIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; STILBENES;

EID: 84942114998     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/1871530315666150316120316     Document Type: Article

References (101)

1. Takaoka, M. The phenolic substances of white hellebore (Veratrum grandiflorum Loes. fil.). J. Faculty Sci. Hokkaido Imperial University, 1940, 3, 1-16.
2. Nonomura, S.; Kanagawa, H.; Makimoto, A. Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-jokon (Polygonum cuspidatum Sieb. Et Zucc.). Yakugaku Zasshi, 1963, 83, 988-990.
3. Langcake, P.; Pryce, R.J. The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol. Plant Pathol., 1976, 9, 77-86.
4. Crozier, A.; Kamiya, Y.; Bishop, G.; Yokota, T. In: Biochemistry and Molecular Biology of Plants; Buchanan, B.B.; Gruissem, W. and Lones, R.L. Ed.; Wiley & Sons: New York, 2000; pp. 851-865.
5. Kimura, Y.; Okuda, H.; Arichi, S. Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim. Biophys. Acta, 1985, 834, 275-278.
6. Siemann, E.H.; Creasy, L.L. Concentration of the phytoalexin resveratrol in wine. Am. J. Eno. Vitic., 1992, 43, 49-52.
7. Jang, M.; Cai, L.; Udeani, G.O.; Slowing, K.V.; Thomas, C.F.; Beecher, C.W.W.; Fong, H.H.; Farnsworth, N.R.; Kinghorn, A.D.; Mehta, R.G.; Moon, R.C.; Pezzuto, J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 1997, 275, 218-220.
8. Subbaramaiah, K.; Chung, W.J.; Michaluart, P.; Telang, N.; Tanabe, T.; Inoue, H.; Jang, M.; Pezzuto, J.M.; Dannenberg, A.J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem., 1998, 273, 21875-21882.
9. Bradamante, S.; Barenghi, L.; Villa, A. Cardiovascular protective effects of resveratrol. Cardiovasc. Drug Rev., 2004, 22, 169-188.
10. Wang, Q.; Xu, J.; Rottinghaus, G.E.; Simonyi, A.; Lubahn, D.; Sun, G.Y.; Sun A.Y. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res., 2002, 958, 439-447.
11. Sinha, K.; Chaudhary, G.; Gupta, Y.K. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci., 2002, 71, 655-665.
12. Inoue, H.; Jiang, X.F.; Katayama, T.; Osada, S.; Umesono, K.; Namura, S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor iiin mice. Neurosci. Lett., 2003, 352, 203-206.
13. Stoclet, J.C.; Chataigneau, T.; Ndiaye, M.; Oak, M.H.; El Bedoui, J.; Chataigneau, M.; Schini-Kerth, V.B. Vascular protection by dietary polyphenols. Eur. J. Pharmacol., 2004, 500, 299-313.
14. Cordova, A.C.; Jackson, L.S.; Berke-Schlessel, D.W.; Sumpio, B.E. The cardiovascular protective effect of red wine. J. Am. Coll. Surg., 2005, 200, 428-439.
15. Opie, L.H.; Lecour, S. The red wine hypothesis: from concepts to protective signaling molecules. Eur. Heart J., 2007, 28, 1683-1693.
16. St. Leger, A.S.; Cochrane, A.L.; Moore, F. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. Lancet, 1979, 1, 1017-1020.
17. Richard, J.L. Coronary risk factors. The French paradox. Arch. Mal. Coeur. Vaiss., 1987, 80, 17-21.
18. Sato, M.; Maulik, N.; Das, D.K. Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants. Ann. N.Y. Acad. Sci., 2002, 957, 122-135.
19. Kopp, P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur. J. Endocrinol., 1998, 138, 619-620.
20. Fremont, L. Biological effects of resveratrol. Life Sci., 2000, 66, 663-673.
21. Inoue, H.; Tanabe, T.; Umesono, K. Feedback control of cyclooxygenase-2 expression through PPARc. J. Biol. Chem., 275, 28028-28032.
22. Tsukamoto, T.; Nakata, R.; Tamura, E.; Kosuge, Y.; Kariya, A.; Katsukawa, M.; Mishima, S.; Itoh, T.; Iinuma, M.; Akao, Y.; Nozawa. Y.; Arai, Y.; Namura, S.; Inoue, H. Vaticanol C, a resveratrol tetramer, activates PPARrrand PPARa///in vitro and in vivo. Nutr. & Metab., 2010, 7, 46.
23. Okazaki, M.1.; Iwasaki, Y.; Nishiyama, M.; Taguchi, T.; Tsugita, M.; Nakayama, S.; Kambayashi, M.; Hashimoto, K.; Terada, Y. PPARbeta/delta regulates the human SIRT1 gene transcription via Sp1. Endocr J., 2010, 57, 403-413.
24. Liang, Y.C.; Huang, Y.T.; Tsai, S.H.; Lin-Shiau, S.Y.; Chen, C.F.; Lin, J.K. Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis, 1999, 20, 1945-1952.
25. Woo, K.J.; Jeong, Y.J.; Inoue, H.; Park, J.W.; Kwon, T.K. Chrysin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression through the inhibition of nuclear factor for IL-6 (NF-IL6) DNAbinding activity. FEBS Lett., 2005, 579, 705-711.
26. Yamamoto, K.; Wang, J.; Yamamoto, S.; Tobe, H. Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid. FEBS Lett., 2000, 465, 103-106.
27. Liang, Y.C.; Tsai, S.H.; Tsai, D.C.; Lin-Shiau, S.Y.; Lin, J.K. Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptorgamma by flavonoids in mouse macrophages. FEBS Lett., 2001, 496, 12-18.
28. Yajima, H.; Ikeshima, E.; Shiraki, M.; Kanaya, T.; Fujiwara, D.; Odai, H.; Tsuboyama-Kasaoka, N.; Ezaki, O.; Oikawa, S.; Kondo, K. Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance. J. Biol. Chem., 2004, 279, 33456-33462.
29. Hotta, M.; Nakata, R.; Katsukawa, M.; Hori, K.; Takahashi, S.; Inoue, H. Carvacrol, a component of thyme oil, activates PPARs and aaand suppresses COX-2 expression. J. Lipid. Res., 2010, 51, 132-139.
30. Katsukawa, M.; Nakata, R.; Takizawa, Y.; Hori, K.; Takahashi, S.; Inoue, H. Citral, a component of lemongrass oil, activates PPARI and aaand suppresses COX-2 expression. Biochim. Biophys. Acta, 2010, 1801, 1214-1220.
31. Katsukawa, M.; Nakata, R.; Koeji, S.; Hori, K.; Takahashi, S.; Inoue, H. Citronellol and geraniol, components of rose oil, activates PPARaaand aaand suppress cyclooxygenase-2 expression. Biosci. Biotech. Biochem., 2011, 75, 1010-1012.
32. Lastra, C.A.; Villegas, I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol. Nutr. Food Res., 2005, 49, 405-430.
33. Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov., 2006, 5, 493-506.
34. Horio, Y.; Hayashi, T.; Kuno, A.; Kunimoto, R. Cellular and molecular effects of sirtuins in health and disease. Clin. Sci., 2011, 121, 191-203.
35. Hubbard, B.P.; Sinclair, D.A. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol. Sci., 2014, 35, 146-154.
36. Smith, W.L. Nutritionally essential fatty acids and biologically indispensable cyclooxygenases. Trends Biochem. Sci., 2008, 33, 27-37.
37. Simmons, D.L.; Botting, R.M.; Hla, T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev., 2004, 56, 387-437.
38. Inoue, H.; Nanayama, T.; Hara, S.; Yokoyama, C.; Tanabe, T. The cAMP response element plays an essential role in the expression of the human prostaglandin-endoperoxide synthase 2 gene in differentiated U937 monocytic cells. FEBS Lett., 1994, 350, 51-54.
39. Inoue, H.; Yokoyama, C.; Hara, S.; Tone, Y.; Tanabe, T. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J. Biol. Chem., 1995, 270, 24965-24971.
40. Inoue, H.; Tanabe, T. Transcriptional role of the nuclear factor kappa B site in the induction by lipopolysaccharide and suppression by dexamethasone of cyclooxygenase-2 in U937 cells. Biochem. Biophys. Res. Commun., 1998, 244, 143-148.
41. Inoue, H.; Umesono, K.; Nishimori, T.; Hirata, Y.; Tanabe, T. Glucocorticoid-mediated suppression of the promoter activity of the cyclooxygenase-2 gene is modulated by expression of its receptor in vascular endothelial cells. Biochem. Biophys. Res. Commun., 1999, 254, 292-298.
42. Oshima, M.; Dinchuk, J.E.; Kargman, S.L.; Oshima, H.; Hancock, B.; Kwong, E.; Trzaskos, J.M.; Evans, J.F.; Taketo, M.M. Suppression of intestinal polyposis in ApcSS716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 1996, 87, 803-809.
43. Morham, S.G.; Langenbach, R.; Loftin, C.D.; Tiano, H.F.; Vouloumanos, N.; Jennette, J.C.; Mahler, J.F.; Kluckman, K.D.; Ledforci, A.; Lee, C.A.; Smithies, O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell, 1995, 83, 473-482.
44. Dinchuk, J.E.; Car, B.D.; Focht, R.J.; Johnston, J.J.; Jaffee, B.D.; Covington, M.B.; Contel, N.R.; Eng, V.; Collins, R.J.; Czerniak, P.M.; Gorry, S.A.; Trzaskos, J.M. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature, 1995, 378, 406-409.
45. Lim, H.; Paria, B.C.; Das, S.K.; Dinchuk, J.E.; Langenbach, R.; Trzaskos, J.M.; Dey, S.K. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell, 1997, 91, 197-208.
46. Dubois, R.N.; Abramson, S.B.; Crofford, L.; Gupta, R.A.; Simon, L.S.; Van De Putte, L.B.A.; Lipskyo, P.E. Cyclooxygenase in biology and disease. FASEB J., 1998, 12, 1063-1073.
47. Grosser, T.; Fries, S.; Fitzgerald, G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest., 2006, 116, 4-15.
48. Inoue, H.; Taba, Y.; Miwa, Y.; Yokota C.; Miyagi, M.; Sasaguri, T. Transcriptional and posttranscriptional regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 1415-1420.
49. Taba, Y.; Sasaguri, T.; Miyagi, M.; Abumiya, T.; Miwa, Y.; Ikeda, T.; Mitsumata, M. Fluid shear stress induces lipocalin-type prostaglandin D2 synthase expression in vascular endothelial cells. Circ. Res., 2000, 86, 967-973.
50. Sun, H.; Sheveleva, E.; Xu, B.; Inoue, H.; Bowden, T.G.; Chen, Q.M. Corticosteroids induced COX-2 expression in cardiomyocytes: role of glucocorticoid receptor and C/EBP/. Am. J. Physiol. Cell Physiol., 2008, 295, C915-C922.
51. Yoshikawa, N.; Nagasaki, M.; Sano, M.; Tokudome, S.; Ueno, K.; Shimizu, N.; Imoto, S.; Miyano, S.; Suematsu, M.; Fukuda, K.; Morimoto, C.; Tanaka, H. Ligand-based gene expression profiling reveals novel roles of glucocorticoid receptor in cardiac metabolism. Am. J. Physiol. Endocrinol. Metab., 2009, 296, E1363-E1373.
52. Tokudome, S.; Sano, M.; Shinmura, K.; Matsuhashi, T.; Morizane, S.; Moriyama, H.; Tamaki, K.; Hayashida, K.; Nakanishi, H.; Yoshikawa, N.; Shimizu, N.; Endo, J.; Katayama, T.; Murata, M.; Yuasa, S.; Kaneda, R.; Tomita, K.; Eguchi, N.; Urade, Y.; Asano, K.; Utsunomiya, Y.; Suzuki, T.; Taguchi, R.; Tanaka, H.; Fukuda, K. Glucocorticoid protects rodent hearts from ischemia/reperfusion injury by activating lipocalin-type prostaglandin D synthasederived PGD2 biosynthesis. J. Clin. Invest., 2009, 119, 1477-1488.
53. Solomon, S.D.; McMurray, J.J.; Pfeffer, M.A.; Wittes, J.; Fowler, R.; Finn, P.; Anderson, F.; Zauber, A.; Hawk, E.; Bertagnolli, M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med., 2005, 352, 1071-1080.
54. Bresalier, R.S.; Sandler, R.S.; Quan, H.; Bolognese, J.A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M.A.; Baron, J.A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med., 2005, 352, 1092-1102.
55. Szewczuk, L.M.; Forti, L.; Stivala, L.A.; Penning, T.M. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2. J. Biol. Chem., 2004, 279, 22727-22737.
56. Tiano, H.F.; Loftin, C.D.; Akunda, J.; Lee, C.A.; Spalding, J.; Sessoms, A.; Dunson, D.B.; Rogan, E.G.; Morham, S.G.; Smart, R.C.; Langenbach, R. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res., 2002, 62, 3395-3401.
57. Leon-Reyes, A.; Van der Does, D.; De Lange, E.S.; Delker, C.; Wasternack, C.; Van Wees, S.C.M.; Ritsema, T.; Pieterse, C.M.J. Salicylate-mediated suppression of jasmonate-responsive gene expression in Arabidopsis is targeted downstream of the jasmonate biosynthesis pathway. Planta, 2010, 232, 1423-1432.
58. Belhadj, A.1.; Telef, N.; Saigne, C.; Cluzet, S.; Barrieu, F.; Hamdi, S.; Merillon, J. Effect of methyl jasmonate in combination with carbohydrates on gene expression of PR proteins, stilbene and anthocyanin accumulation in grapevine cell cultures. Plant Physiol. Biochem., 2008, 46, 493-499.
59. Kopp, E.1.; Ghosh, S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science, 1994, 265, 956-959.
60. Hawley, S.A.; Fullerton, M.D.; Ross, F.A.; Schertzer, J.D.; Chevtzoff, C.; Walker, K.J.; Peggie, M.W.; Zibrova, D.; Green, K.A.; Mustard, K.J.; Kemp, B.E.; Sakamoto, K.; Steinberg, G.R.; Hardie, D.G. The ancient drug salicylate directly activates AMPactivated protein kinase. Science, 2012, 336, 918-922.
61. Mangelsdorf, D.J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; Evans R.M. The nuclear receptor superfamily: the second decade. Cell, 1995, 83, 835-839.
62. Michalik, L.; Auwerx, J.; Berger, J.P.; Chatterjee, V.K.; Glass, C.K.; Gonzalez, F.J.; Grimaldi, P.A.; Kadowaki, T.; Lazar, M.A.; O'rahilly, S.; Palmer, C.N.A.; Plutzky, J.; Reddy, J.K.; Spiegelman, B.M.; Staels, B.; Wahli, W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev., 2006, 58, 726-741.
63. Sonoda, J.; Pei, L.; Evans, R.M. Nuclear receptors: decoding metabolic disease. FEBS Lett., 2008, 582, 2-9.
64. Forman, B.M.; Tontonoz, P.; Chen, J.; Brun, R.P.; Spiegelman, B.M.; Evans, R.M. 15--BBBBBB12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARt. Cell, 1995, 83, 803-812.
65. Kliewer, S.A.; Lenhard, J.M.; Wilson, T.M.; Patel, I.; Morris, D.C.; Lehmann, J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell, 1995, 83, 813-819.
66. Hertz, R.; Berman, I.; Keppler, D; Bar-Tana, J. Activation of gene transcription by prostacyclin analogues is mediated by the PPAR. Eur. J. Biochem., 1996, 235, 242-247.
67. Callejas, N.A.; Castrillo, A.; Bosca, L.; Martin-Sanz, P. Inhibition of prostaglandin synthesis up-regulates cyclooxygenase-2 induced by lipopolysaccharide and peroxisomal proliferators. J. Pharmacol. Exp. Ther., 1999, 288, 1235-1241.
68. Meade, E.A.; McIntyre, T.M.; Zimmerman, G.A.; Prescott, S.M. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J. Biol. Chem., 1999, 274, 8328-8334.
69. Chinery, R.; Coffey, R.J.; Graves-Deal, R. Kirkland, S.C.; Sanchez, S.C.; Zackert, W.E.; Oates, J.A.; Morrow, J.D. Prostaglandin J2 and 15-deoxy-a12, 14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res., 1999, 59, 2739-2746.
70. Itoh, K.; Mochizuki, M.; Ishii, Y.; Ishii, T.; Shibata, T.; Kawamoto, Y.; Kelly, V.; Sekizawa, K.; Uchida, K.; Yamamoto, M. Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-e12, 14-prostaglandin J2. Mol. Cell Biol., 2004, 24, 36-45.
71. Staels, B.; Koenig, W.; Habib, A.; Merval, R.; Lebret, M.; Torra, I.P.; Delerive, P.; Fadel, A.; Chinetti, G.; Fruchart, J-C.; Najib, J.; Maclouf, J.; Tedgui, A. Activation of human aortic smooth-muscle cells is inhibited by PPARccbut not by PPARbbactivators. Nature, 1998, 393, 790-793.
72. Marx, N.; Sukhova, G.; Collins, T.; Libby, P.; Plutzky, J. PPAR activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation, 1999, 99, 3125-3131.
73. Van Ginderachter, J.A.; Meerschaut, S.; Liu, Y.; Brys, L.; Groeve, K.D.; Ghassabeh, G.H.; Raes, G.; Baetselier, P.D. PPARKKligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood, 2006, 108, 525-535.
74. Bouhlel, M.A.; Derudas, B.; Rigamonti, E.; Dievart, R.; Brozek, J.; Haulon, S.; Zawadzki, C.; Jude, B.; Torpier, G.; Marx, N.; Staels, B.; Chinetti-Gbaguidi, G. PPARBBactivation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab., 2007, 6, 137-143.
75. Kang, K.; Reilly, S.M.; Karabacak, V.; Gangl, M.R.; Fitzgerald, K.; Hatano, B.; Lee, C-H. Adipocyte-derived Th2 cytokines and myeloid PPARmmregulate macrophage polarization and insulin sensitivity. Cell Metab., 2008, 7, 485-495.
76. Odegaard, J.I.; Ricardo-Gonzalez, R.R.; Eagle, A.R.; Vats, D.; Morel, C.R.; Goforth, M.H.; Subramanian, V.; Mukundan, L.; Ferrante, A.W.; Chawla1, A. Alternative M2 activation of Kupffer cells by PPARccameliorates obesity-induced insulin resistance. Cell Metab., 2008, 7, 496-507.
77. Kuwamoto, S.; Inoue, H.; Tone, Y.; Izumi, Y.; Tanabe T. Inverse gene expression of prostacyclin and thromboxane synthases in resident and activated peritoneal macrophages. FEBS Lett., 1997, 409, 242-246.
78. Fournier, T.; Fadok, V.; Henson, P.M. TNF-α inversely regulates prostaglandin D2 and prostaglandin E2 production in murine macrophages. Synergistic action of cyclic AMP on cyclooxygenase-2 expression and prostaglandin E2 synthesis. J. Biol. Chem., 1997, 272, 31065-31072.
79. Jakobsson, P.J.; Thoren, S.; Morgenstern, R.; Samuelsson, B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. USA., 1999, 96, 7220-7225.
80. Murakami, M.; Naraba, H.; Tanioka, T.; Semmyo, N.; Nakatani, Y.; Kojima, F.; Ikeda, T.; Fueki, M.; Ueno, A.; Oh-ishi, S.; Kudo, I. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem., 2000, 275, 32783-32792.
81. Uematsu, S.; Matsumoto, M.; Takeda, K.; Akira, S. Lipopolysaccharide-dependent prostaglandin E2 production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J. Immunol., 2002, 68, 5811-5816.
82. Diaz-Munoz, M.D.; Osma-Garcia, I.C.; Fresno, M.; Iniguez, M.A. Involvement of PGE2 and the cAMP signalling pathway in the upregulation of COX-2 and mPGES-1 expression in LPS-activated macrophages. Biochem. J., 2012, 443, 451-461.
83. Nishimura, T.; Zhao, X.; Gan, H.; Koyasu, S.; Remold, H.G. The prostaglandin E2 receptor EP4 is integral to a positive feedback loop for prostaglandin E2 production in human macrophages infected with Mycobacterium tuberculosis. FASEB J., 2013, 27, 3827-3836.
84. Lancon, A.; Kaminski, J.; Tili, E.N.; Michaille, J-J.; Latruffe, N. Control of microRNA expression as a new way for resveratrol to deliver its beneficial effects. J. Agric. Food Chem., 2012, 60, 8783-8789.
85. Tili, E.; Michaille, J-J.; Adair, B.; Alder, H.; Limagne, E.; Taccioli, C.; Ferracin, M.; Delmas, D.; Latruffe, N.; Croce, C.M. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis, 2010, 31, 1561-1566.
86. Hagiwara, K.1.; Kosaka, N.; Yoshioka, Y.; Takahashi, R.; Takeshita, F.; Ochiya, T. Stilbene derivatives promote Ago2-dependent tumour-suppressive microRNA activity. Sci. Rep., 2012, 2, 314.
87. Shah, Y.M.; Morimura, K.; Yang, Q.; Tanabe, T.; Takagi, M.; Gonzalez, F.J. Peroxisome proliferator-activated receptor G regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol. Cell Biol., 2007, 27, 4238-4247.
88. Yin, K.J.; Deng, Z.; Hamblin, M.; Xiang, Y.; Huang, H.; Zhang, J.; Jiang, X.; Wang, Y.; Chen, Y.E. Peroxisome Proliferator-Activated Receptor ccregulation of miR-15a in ischemia-induced cerebral vascular endothelial injury. J. Neurosci., 2010, 30, 6398-6408.
89. Thulin, P.1.; Wei, T.; Werngren, O.; Cheung, L.; Fisher, R.M.; Grander, D.; Corcoran, M.; Ehrenborg, E. MicroRNA-9 regulates the expression of peroxisome proliferator-activated receptor δ in human monocytes during the inflammatory response. Int. J. Mol. Med., 2013, 31, 1003-1010.
90. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L-L.; Scherer, B.; Sinclair, D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003, 425, 191-196.
91. Wood, J.G.; Rogina, B.; Lavu, S.; Howitz, K.; Helfand, S.L.; Tatar, M.; Sinclair, D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature, 2004, 430, 686-689.
92. Kaeberlein, M.; McDonagh, T.; Heltweg, B.; Hixon, J.; Westman, E.A.; Caldwell, S.D.; Napper, A.; Curtis, R.; DiStefano, P.S.; Fields, S.; Bedalov, A.; Kennedy, B.K. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem., 2005, 280, 17038-17045.
93. Pacholec, M.; Bleasdale, J.E.; Chrunyk, B.; Cunningham, D.; Flynn, D.; Garofalo, R.S.; Griffith, D.; Griffor, M.; Loulakis, P.; Pabst, B; Qiu, X.; Stockman, B.; Thanabal, V.; Varghese, A.; Ward, J.; Withka, J.; Ahn K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem., 2010, 285, 8340-8351.
94. Dai, H.; Kustigian, L.; Carney, D. SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J. Biol. Chem., 2010, 285, 32695-32703.
95. Hubbard, B.P.; Gomes, A.P.; Dai, H.; Li, J.; Case, A.W.; Considine, T.; Riera, T.V.; Lee, J.E.; Yen E, S.; Lamming, D.W.; Pentelute, B.L.; Schuman, E.R.; Stevens, L.A.; Ling, A.J.Y.; Armour, S.M.; Michan, S.; Zhao, H.; Jiang, Y.; Sweitzer, S.M.; Blum, C.A.; Disch, J.S.; Ng, P.Y.; Howitz, K.T.; Rolo, A.P.; Hamuro, Y.; Moss, J.; Perni, R.B.; Ellis, J.L.; Vlasuk, G.P.; Sinclair, D.A. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science, 2013, 339, 1216-1219.
96. Corton, J.C.; Apte, U.; Anderson, S.P.; Limaye, P.; Yoon, L.; Latendresse, J.; Dunn, C.; Everitt, J.I.; Voss, K.A.; Swanson, C.; Kimbrough, C.; Wong, J.S.; Gill, S.S.; Chandraratna, R.A.S.; Kwak, M-K.; Kensler, T.W.; Stulnig, T.M.; Steffensen, K.R.; Gustafsson, J-A.; Mehendale, H.M. Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors. J. Biol. Chem., 2004, 279, 46204-46212.
97. Yeung, F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; Frye, R.A.; Mayo, M.W. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J., 2004, 23, 2369-2380.
98. Zhang, R.; Chen, H.Z.; Liu, J.J.; Jia, Y.Y.; Zhang, Z.Q.; Yang, R.F.; Zhang, Y.; Xu, J.; Wei, Y.S.; Liu, D.P.; Liang, C.C. SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J. Biol. Chem., 2010, 285, 7097-7110.
99. Yoshizaki, T.; Schenk, S.; Imamura, T.; Babendure, J.L.; Sonoda, N.; Bae, E.J.; Oh, D.Y.; Lu, M.; Milne, J.C.; Westphal, C.; Bandyopadhyay, G.; Olefsky, J.M. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am. J. Physiol. Endocrinol. Metab., 2010, 298, E419-E428.
100. Purushotham, A.; Schug, T.T.; Xu, Q.; Surapureddi, S.; Guo, X.; Li, X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab., 2009, 9, 327-338.
101. Park, S.J.; Ahmad, F.; Philp, A.; Baar, K.; Williams, T.; Luo, H.; Ke, H.; Rehmann, H.; Taussig, R.; Brown, A.L.; Kim, M.K.; Beaven, M.A.; Burgin, A.B.; Manganiello, V.; Chung, J.H. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell, 2012, 148, 421-433.